SD 254

Drug Profile

SD 254

Alternative Names: Deuterated venlafaxine; SD-254; Venlafaxine deuterium-substituted

Latest Information Update: 15 Jan 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Auspex Pharmaceuticals
  • Class Antidepressants; Cyclohexanols; Dimethylamines; Organic deuterium compounds; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Major depressive disorder
  • Discontinued Neuropathic pain

Most Recent Events

  • 15 Jan 2015 Discontinued - Phase-I for Neuropathic pain in USA (PO)
  • 15 Jul 2013 Phase-I clinical trials in Neuropathic pain in USA (PO)
  • 24 Oct 2010 No development reported - Phase-I for Major depressive disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top